Emerging research suggest Retatrutide , a dual agonist targeting both GLP-1 and GIP , appears to represent a notable advancement for obesity loss . Preliminary patient investigations have indicated substantial losses in body fat , conceivably surpassing existing obesity treatments. However , furt